A prototype of DNA nanorobot with the ability to transport molecular payloads was designed to target cancer cells in tissue culture. Moreover, a further step was taken to succeed in the first in vivo application of the DNA nanorobot for cancer therapy. The robot was constructed using aptamer and DNA origami to fold a 90-nm tubular device to carry the blood coagulation protease thrombin inside, shielded from circulating platelets and plasma fibrinogen. The recognition and binding of the aptamer to its tumourspecific target molecule triggered the robot unfolding to expose thrombin to the blood, which in turn activated coagulation at the local tumour site, resulting in tumour necrosis and inhibition of tumour growth. Since all solid-tumour feeding vessels are virtually the same, this strategy could be effective against many types of malignant diseases.
| INTRODUCTION
An ideal drug delivery system would be capable of preserving the activity of drug molecules by protecting them against degradation, mitigating toxicity and other biological side effects of drug molecules as well as specifically targeting cells and controlling drug release. So far, a series of nanocarriers, for example, liposomes, cationic dendric polymers, gold nanoparticles and carbon nanomaterials, has been developed for drug delivery in various diseases therapy. However, each of them has some limitation, such as the immune toxicity induced by the heterogeneous size distribution of the liposome carriers, or the safety concerns caused by the toxic elements or residuals of the inorganic nanoparticles. Although containing multiple components -scaffold, staple, fastener/sensor, payload and even label for imaging, the DNA nanorobot was self-assembled in one step with a uniform size, which was neat and visualized by atomic force microscopy. 3 The system was called a robot because it can sense the environmental information and decide when, where and whether to act. The thrombin payload was a serine protease that regulated platelet aggregation by activating platelets and converting circulating fibrinogen into insoluble fibrin, leading to vascular blockage 7 ( Figure 1B) . Because of its indiscriminative effects and short circulation half-life, thrombin had been removed from cancer treatment before. With this DNA nanorobot, to precisely deliver thrombin solely to tumour sites in a highly controlled autonomous manner was managed to maximize its biostability and drug efficacy as well as minimize its toxicity. 3 The approach in principle was applicable to deliver a wide range of drug candidates that had been previously excluded from clinical use because of unwanted stability issues or side effects.
The nanorobot was confirmed to function well by investigating 
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